Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The funding is intended to advance the clinical development of HU6, a controlled metabolic accelerator (CMA) designed to address obesity, a primary driver of cardio-metabolic disease Rivus Pharmaceuticals Inc
GLP-1 also slows down the movement of food from the stomach to the small intestine hence a feeling of fullness and increases insulin production, lowering blood sugar
Program Operations and Oversight Due to financial limitations, the program requires stringent management
This should only be done under the supervision of a healthcare professional
US$ 22.10
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
US$ 23.56
US$ 25.48
US$ 22.80
US$ 23.03
US$ 28.66
US$ 27.70
US$ 23.86
US$ 24.63
